Sponsored Links
| Edison Pharmaceuticals Announces Results Of EPI-A0001 Phase 2A Double Blind Placebo Controlled 28-Day Clinical Trial In The Mitochondrial Disease |
 |
 |
 |
| Pharmacy - Pharma Industry - Biotech Industry | |||
|
Edison Pharmaceuticals, Inc. announced preliminary results obtained on a 28-day phase 2A clinical trial in Friedreich's ataxia. While the primary endpoint of glucose disposition index (a measure of glucose handling by the body) did not show statistically significant improvement, EPI-A0001 did significantly improve neurological function as assessed by the Friedreich's Ataxia Rating Scale (FARS)... Read more: Pharma Industry / Biotech Industry News From Medical News Today
|